INSM vs SVRA
INSM: A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases. SVRA: Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
Side-by-side fundamentals
| Metric | INSM | SVRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $106.64 | $5.65 | |
| Market cap as of 2026-07-23 | $23.4B | $1.2B | |
| PEG as of 2026-07-23 | n/a | -0.81 | |
| Net margin as of 2026-07-23 | -144.4% | -4253.9% | INSM higher |
| Gross margin as of 2026-07-23 | +81.8% | +100.0% | SVRA higher |
| Operating margin as of 2026-07-23 | -140.6% | -4150.0% | INSM higher |
| ROE as of 2026-07-23 | -130.1% | -87.2% | SVRA higher |
| ROA as of 2026-07-23 | -51.6% | -66.4% | INSM higher |
| Debt / equity as of 2026-07-23 | 1.03 | 0.17 | SVRA lower |
| Revenue growth (YoY) as of 2026-07-23 | +115.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +35.2% | n/a | |
| Beta as of 2026-07-23 | 0.80 | 0.25 | |
| 1-year return as of 2026-07-22 close | +5.7% | +134.4% | SVRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.